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This thesis aimed to elucidate the demographic characteristics associated with 
elevated or reduced rates of pneumococcal conjugate 13 (PCV13) vaccination. 
A retrospective cohort study was performed using the Truven Health 
MarketScan® Database. Three cohorts were created corresponding to populations for 
which the CDC recommends PCV13 vaccination. Cohort 1: children < 36 months of age. 
Cohort 2: adults 19-64 years of age with high infection risk. Cohort 3: adults > 65 years 
of age. Odds of having a PCV13 claim were calculated for each cohort.  
For Cohort 1, 78% out of a total of 353,214 subjects had a sufficient number of 
PCV13 doses to meet CDC recommendations. For Cohort 2, 3.7% out of a total of 
673,157 subjects had a PCV13 claim. For Cohort 3, 18% of 1,262,531 subjects had a 
PCV13 claim. Odds of vaccination were generally lower in younger subjects, those with 
fewer outpatient claims, and those with residence in the Northeast and South regions. In 
Cohort 2, odds were reduced in subjects with generalized malignancy. Gender and urban 
residence were poor predictors of vaccination status.  
By understanding the demographic factors associated with lower rates of 
vaccination, clinicians may more effectively direct their efforts to increase pneumococcal 
vaccination coverage.  
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Section One: Introduction 
Streptococcus pneumoniae (pneumococcus) is a gram-positive facultative 
anaerobic bacteria, and is common cause of otitis media, pneumonia, meningitis, 
osteomyelitis, and bacteremia, with the latter three collectively referred to as invasive 
pneumococcal disease (IPD).1-3 Two pneumococcal vaccines are presently recommended 
for use in the U.S. by the Centers for Disease Control and Prevention (CDC), the 
pneumococcal polysaccharide 23-valent vaccine (PPSV23) and the pneumococcal 
polysaccharide conjugate 13-valent vaccine (PCV13).1 The CDC has developed 
administration recommendations for each of these vaccines based on patient age and 
health status.1 The United States Department of Health and Human Services has 
incorporated pneumococcal recommendations into their Healthy People 2020 goals.4 
Unfortunately, estimates of pneumococcal vaccination coverage fall below goals.5-7 This 
thesis aims to elucidate the demographic characteristics associated with lower and higher 
rates of PCV13 vaccination, so that populations experiencing lower rates of vaccination 
can be better addressed. 
Pneumococcal Disease 
Despite pneumococcal vaccination’s significant impact on reducing cases of IPD 
and pneumonia, pneumococcus remains an important clinical pathogen, and continues to 
pose an elevated threat to young, elderly, and immunocompromised persons. 
Pneumococcus causes between 10-36% of pneumonias in the US.1,3,8 During 2004, 
approximately 400,000 inpatient pneumococcal pneumonia cases occurred, resulting in 
approximately 24,000 deaths.9,10 During 2013, approximately 34,000 cases of IPD were 
reported in the U.S., with approximately 3,700 resultant deaths. Active Bacterial Core 
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Surveillance (ABCs) Report Emerging Infections Program Network, Streptococcus 
pneumoniae, 2013.11 
Persons with immunocompromising conditions carry greater risk of infection and 
higher treatment costs compared to their healthy counterparts. Adults aged 19-64 with 
moderate and high infection risk conditions, defined in Appendix A, respectively, have 
rates of all-cause pneumonia 4 and 7 times greater than their healthy counterparts.12 
These patients also have 9 and 26 times greater rates of IPD development, respectively, 
and 1.6 and 3 times greater inpatient treatment costs.12,13 Additionally, males appear to 
carry 1.5 to 2 times greater risk of all-cause pneumonia compared to female subjects, 
with the greatest risk in males ages <2 and 40–64.11 The cause of this increased incidence 
in males is unknown, but may be related to hormonal differences and gender related 
social behaviors.14 
Pneumococcal Vaccines and CDC Recommendations 
The older of the two currently recommended vaccines is PPSV23, brand name 
Pneumovax 23®, and was approved by the U.S. Food and Drug Administration (FDA) in 
1983. The newer of the two currently used vaccines is PCV13, brand name Prevnar 13®, 
and was approved by the FDA in February 2010. An additional vaccine of historical 
importance is the pneumococcal polysaccharide conjugate 7-valent vaccine (PCV7), 
brand name Prevnar®. Introduced in 2000, it is the predecessor to PCV13, and was 
phased out of use following the introduction of PCV13. 
Pathogenic pneumococcus strains are encapsulated by complex polysaccharides. 
Capsular polysaccharides are antigenic in humans, and are grouped into serotypes. 
Vaccines against pneumococcus can be created by purifying capsular polysaccharides. 
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Such vaccines do not provide universal protection against all pneumococcus types, only 
against the serotypes it contains.1,2 PPSV23, PCV7, and PCV13 are all polysaccharide 
containing vaccines, with the numbers 23, 7 and 13 indicating the number of serotypes 
covered. PCV13 contains 12 serotypes from PPSV23, plus one additional serotype. All of 
the serotypes in PCV7 are contained in PPSV23 and PCV13. Serotype coverage for all 
three vaccines is listed in Appendix B. 
In contrast to PPSV23, in PCV7 and PCV13 the polysaccharides components are 
bound to a protein based nontoxic diphtheria toxin; this increases its antigenicity and 
allows it to be administered at younger ages than PPSV23. In cases where both vaccines 
are indicated, PCV13 is recommended for administration prior to PPSV23.1 
PPSV23 is recommended by the CDC for all adults 65 years or older and for 
those 2 years or older with moderate-high infection risk conditions (Appendix A). At the 
time of its release, PCV13 was recommended for routine vaccination of children 2-59 
months old and children up to 71 months with underlying medical conditions resulting in 
moderate-high risk for infection, listed in Appendix A).15,16 The recommended course for 
children is a series of four PCV13 injections, three prior to 12 months of age, and one 
after 12 months of age; with recommendations also available for children vaccinated at 
older ages, detailed in Appendix C. In June 2012, the recommendation was expanded to 
include adults 19 and over at high risk for infection. In February 2013 it was expanded 
again to include children 71 months – 18 years of age with high risk for infection.17,18 
Most recently, in September 2014, the CDC again expanded the PCV13 recommendation 
to include all adults 65 years or older.17 The cost of PCV13 varies between $135-
$170.19,20 
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Pneumococcal Vaccination Impact on Pneumococcal Disease  
Prospective epidemiological studies have indicated PCV13, and PCV7, are 
effective in reducing the number of infections caused by the pneumococcal serotypes 
they respectively cover. By 2007, the number of IPD infections caused by the serotypes 
covered by PCV7 were reduced by 97%, and the rate of IPD was reduced by 75% in 
persons <5 years of age. Persons ≥65 years of age, though never the recipients of PCV7, 
also benefited for PCV7 with an 84% reduction in infections caused by the serotypes 
covered by PCV7, and a 35% rate reduction in IPD.21 As a consequence, IPD caused by 
serotypes not included in PCV7 has proportionally increased. Similarly, the introduction 
of PCV13 has resulted in a major reduction of IPD caused by serotypes covered by the 
vaccine, and a relative increase in the rate of IPD caused by non-covered serotypes.22 
Despite the relative increase in IPD cases caused by non-covered serotypes, the overall 
rate of IPD has decreased, which may be attributable to the remaining serotypes overall 
being less virulent (though some, such as serotype 19A, are relatively virulent and 
resistant to antibiotics).23,24 Both PCV13 and PPSV23 exhibit greater efficacy in reducing 
IPD than pneumonia. Among the pediatric population, PCV7 vaccination has also 
reduced frequency of middle ear infections.25 
Pneumococcal Vaccination Coverage 
Prior to 2012, there had never been a pneumococcal conjugate vaccine 
recommended for use in adults; subsequently, pneumococcal vaccination estimates did 
not differentiate between pneumococcal conjugate vaccines and PPSV23, a trend that 
continued even after PCV13 became recommended for adults.  
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From 2012-2014, the Joint Commission required reporting of pneumococcal 
immunization measures; but did not differentiate between PCV13 and PPSV23.26 During 
the 2012 and 2013, the years for which measures were collected, vaccination rates were 
90.6% and 92.5% respectively; however, due to discrepancies in how rates were reported, 
the Joint Commission has stated these reports may not be accurate, and has retired the 
pneumococcal immunization measures.27 
In a 2013 survey of two retirement communities in North Carolina with adults 
≥65 total sample size of 210 persons, 183 (87%) reported receiving PPSV23, 34 (16%) 
reported as immunocompromised, and 1 person (0.4%) reported receiving PCV13.28 
Additional studies in older adults have found disparities in vaccination rates by race and 
metropolitan type, i.e. rural vs. urban residence.29,30 
Two major U.S. government sponsored databases are available which contain 
U.S. pneumococcal vaccines coverage estimates, one from the National Health Interview 
Survey (NHIS), and one from the Behavioral Risk Factor Surveillance System (BRFSS), 
though only the former has had coverage estimates published in recent years. The 2015 
NHIS estimated the PCV13 vaccination rate at 83% in children under 36 months of age, 
and combined PPSV23 and PCV13 pneumococcal vaccination at 23% in adults 19–64 
years of age with moderate-high infection risk conditions, and 64% in adults ≥65.6,7 
These estimates fall below the Target Healthy People 2020 goals for pneumococcal 
vaccination coverage, which are 90% in children under 36 months (IID-7.7), 60% in 
adults 19-64 years of age with moderate-high infection risk conditions (IID-13.2), and 
90% in adults over 65 years of age (IID-13.1).4 In children, this goal refers to vaccination 
with PCV13, and for adults, refers to vaccination with either PCV13 or PPSV23.   
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Section Two: Methods 
Data Source  
A retrospective cohort study was performed using the Truven Health 
MarketScan® Database, years 2010-2015. This de-identified commercial insurance 
database contains patient-level enrollment details, and in-patient and outpatient claims. 
This nationally representative database includes data from commercial insurance 
companies, Blue Cross and Blue Shield plans, third-party administrators (TPAs), and 
Medicare Advantage plans. This study was exempt from review by the University of 
Kentucky Institutional Review Board as it contains only de-identified data that do not 
meet the Department of Health and Human Services (DHHS) definition of human 
subjects or the Food & Drug Administration’s (FDA) definition of human subjects.  
Study Populations 
Three cohorts were created corresponding to populations for which the CDC 
recommends PCV13 vaccination. For all cohorts, gender, region, and urban status, and 
outpatient days are reported. Urban status was determined by residence in a Core Based 
Statistical Area as cataloged by the U.S. Office of Management and Budget.31 Outpatient 
days reflect the total number of unique days on which an outpatient medical service was 
claimed by a provider. 
Cohort 1: Children < 36 months of age whose coverage began at zero years of 
age, and had coverage eight out of every twelve months per calendar year up to 2 years of 
age. Vaccination claims were detected by CPT procedure code ‘90669’ or ‘90670’ 
(pneumococcal conjugate vaccine administration, for subjects under 5 years of age, and 
for subjects of any age respectively) prior to 36 months of age, or ICD-9 diagnosis code 
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‘V0382’ or ‘V066’ (pneumococcal vaccination with and without concurrent influenza 
vaccination respectively) prior to 24 months of age (in subjects over 24 months of age, 
these diagnosis codes may indicate administration of PPSV23). For PCV13 claims to be 
valid, they must have occurred on or after February 10, 2010, the date at which the CDC 
began recommendation of PCV13 vaccination for all persons 2-59 months of age; 
additionally, the claim must have occurred a minimum of 10 days following a previous 
claim. Subjects were categorized based on CDC PCV13 pediatric vaccination 
recommendations, their total number of PCV13 claims, and their age when the claim 
occurred. Subjects with three PCV13 claims prior to age one, plus one claim at one year 
of age, or who met the “catch-up” vaccination criteria listed in Appendix C, were 
categorized as “vaccination complete.” Subjects with at least one PCV13 vaccination 
claim, but who did not have a claim for subsequent doses to suggest completion of CDC 
recommendations by 36 months of age were categorized as “vaccination incomplete.” 
Subjects without any PCV13 claim were categorized as “No PCV13 Claim.” 
Cohort 2: Adults 19-64 years of age with a high infection risk condition, and had 
coverage eight out of every twelve months per calendar year from 2012-2015. Conditions 
must have been included in an outpatient claim between 2012 and 2015 via ICD-9 
diagnosis or CPT service code as listed in Appendix D. Vaccination claims were 
determined by the presence of CPT procedure code 90670, and must have occurred on or 
after June 20, 2012, the date at which the CDC began recommendation of PCV13 
vaccination for persons 19 years of age and older with high infection risk conditions. Age 
was determined on date of vaccination, or for unvaccinated persons, age at the start of 
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2014. Subjects are included in the count of patients with inpatient claim, if that subject 
had at least one inpatient claim made after June 20, 2012. 
Cohort 3: Adults ≥ 65 years of age, and had coverage eight out of every twelve 
months per calendar year from 2012-2015. To be counted as a subject with a high 
infection risk condition, at least one outpatient claim must have been made between 2012 
and 2015 for one of the conditions listed in Appendix D. Vaccination claims were 
determined by the presence of CPT procedure code 90670, and must have occurred on or 
after June 20, 2012; however, for analysis excluding patients with high infection risk 
conditions, vaccination must have occurred on or after August 13, 2014, the date at which 
the CDC began recommendation of PCV13 vaccination for all persons 65 years of age 
and older. 
Statistical Analyses 
For each cohort, the odds of receiving PCV13 to completion was determined. For 
odds ratio analysis, the number of outpatient days was categorized by quartile. For 
Cohort 2, two analyses were performed, the first includes all qualifying subjects, and the 
second excludes subjects with an inpatient claim after June 20, 2012. For Cohort 3, two 
analyses were also performed, the first includes all qualifying subjects, and the second 
excludes subjects with an inpatient claim after June 20, 2012 or with a high infection risk 
condition. Subjects with inpatient claims were excluded in the secondary analyses 
performed for Cohorts 2 and 3, as hospitals may have had standing orders to provide 
PCV13 to qualifying patients, but are unlikely to submit a PCV13 claim. Statistical 
analysis was performed using SAS Enterprise Guide software, Version 7.1 of the SAS 
System for Windows.32  
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Section Three: Results 
Cohort 1: Children < 36 months of age 
A total of 353,214 subjects were identified, with 78% categorized as “vaccination 
complete,” 13% as “vaccination incomplete,” and 9% as “No PCV13 claim” using the 
categories defined in the Cohort 1 methods.  
Table 3.1 provides summary descriptive statistics for the subjects in Cohort 1 and 
is subdivided by vaccination category. The groups show similar proportions of 
individuals with “vaccination complete” status when assessed by gender, region, and 
urban residence. The groups show dissimilar mean number of outpatient days, with 
subjects reaching vaccination completion having a mean of 57% more outpatient claims.  
Table 3.1 Children < 36 Months of Age, Descriptive Table 
Vaccination Status No PCV13 
Claim 
Vaccination 
Incomplete 
Vaccination 
Complete 
All groups  
(% Complete) 
Demographics 
n  30,932   46,604   275,678   353,214 (78.0%)  
Male  15,932   24,104   141,811   181,847 (78.0%)  
Northeast  6,527   8,886   51,346   66,759 (76.9%)  
North Central  5,028   9,048   64,662   78,738 (82.1%)  
South  7,439   15,323   95,043   117,805 (80.7%)  
West  10,028   12,216   57,745   79,989 (72.2%)  
Region Unknown  1,910   1,131   6,882   9,923 (69.4%)  
Urban  24,894   39,640   241,401   305,935 (78.9%)  
Healthcare Utilization 
Outpatient Days Mean 19 26 30 29 
Outpatient Days 
Standard Deviation 
26.75 28.97 32.91 25.10 
 
Table 3.2 provides results from the output of the multiple logistic regression 
model with “vaccination complete” status as the predicted outcome. All covariates were 
significant at the 5% level. Subjects who were female, had residence outside the 
Northeast region, and had urban residence, had greater odds being categorized as 
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“vaccination complete.” Subjects with more outpatient visit days progressively had 
greater odds of vaccination. 
Table 3.2 Children < 36 Months of Age, Odds of Receiving PCV13 to Completion 
Effect Odds Ratio Estimate 95% CI 
Demographics 
Male vs Female *0.921 0.906 0.936  
North Central vs Northeast *1.640 1.597 1.685 
South vs Northeast *1.342 1.311 1.375 
West vs Northeast *1.034 1.009 1.060 
Region Unknown vs Northeast *1.145 1.085 1.208 
Urban vs Rural *1.464 1.427 1.502 
Healthcare Utilization 
Outpatient days 2nd vs 1st quartile† *2.871 2.809 2.935 
Outpatient days 3rd vs 1st quartile† *3.466 3.386 3.547 
Outpatient days 4th vs 1st quartile† *3.634 3.549 3.721 
C-statistic = 0.661 
†Quartile breakpoints are <18, 18-24, 25-34, and > 34 days, for quartiles 1-4 respectively 
*Denotes significant value 
Cohort 2: Adults 19-64 years of age with high risk indication 
An initial pool of 8,214,322 subjects 19-64 years of age was identified with 
continuous enrollment 2012-2015, of these, 673,157 had a high infection risk condition, 
3.7% of which had a PCV13 claim.  
Table 3.3 provides summary descriptive statistics for the subjects in Cohort 2. The 
table is subdivided by year of PCV13 claim. PCV13 claim rates appear similar by gender, 
region, and urban residence. Subjects with a PCV13 claim had a mean 34% greater 
number of outpatient claim days compared to subjects without a vaccination claim. 
Subjects over 50 years of age tend to have higher rates of PCV13 claims compared to 
those in lower age groups. Rate of PCV13 claims varied by diagnosis between 2.2% and 
21.4%, with the lowest rates observed in subjects with sickle cell disease or other 
hemoglobinopathies, and highest rate in subjects who are human immunodeficiency virus 
(HIV) positive. 
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Table 3.3 Adults 19-64 Years of Age with High Risk Indication, Descriptive Table 
Year of PCV13 Claim None 2012 2013 2014 2015 All groups  
(% vaccinated) 
Demographics 
n 614,045   557   3,210   5,186  15,410  638,408 (3.8%) 
Age Mean  52  51   49   52   56  52 
Age Standard Deviation 9.47 9.26 9.40 9.55 8.02 9.45 
Age 19-29  18,616   26   114   172   215  19,143 (2.8%) 
Age 30-39  50,148   42   353   385   569  51,497 (2.6%) 
Age 40-49 119,595   103   862   959   1,700  123,219 (2.9%) 
Age 50-59 261,834   304   1,406   2,142   5,834  271,520 (3.6%) 
Age 60-64 163,852   82   475   1,528   7,092  173,029 (5.3%) 
Male 257,127   296   2,079   2,867   7,419  269,788 (4.7%) 
Female 356,918   261   1,131   2,319   7,991  368,620 (3.2%) 
Northeast 137,654   117   604   1,095   3,132  142,602 (3.5%) 
North Central 118,997   107   582   1,140   3,540  124,366 (4.3%) 
South 268,962   248   1,502   2,058   6,078  278,848 (3.5%) 
West  87,009   85   514   882   2,649  91,139 (4.5%) 
Region Unknown  1,423   -     8   11   11  1,453 (2.1%) 
Urban 542,841   500   2,941   4,692  13,695  564,669 (3.9%) 
Rural  70,286   57   269   494   1,704  72,810 (3.5%) 
Healthcare Utilization 
Outpatient Days Mean  71   93   82   94   98  71 
Outpatient Days 
Standard Deviation 
67.32 73.91 81.30 83.14 85.50 68.20 
# of Patients with 
Inpatient Claim 
183,003   169   969   1,919   6,057  192,117 (4.7%) 
Diagnosis 
Cochlear Implant  1,245   1   59   56   96  1,457 (14.6%) 
Cerebrospinal Fluid 
Leak 
 3,228   3   6   18   52  3,307 (2.4%) 
Asplenia  1,342   5   53   74   169  1,643 (18.3%) 
Sickle Cell Disease or 
Other 
Hemoglobinopathy 
 19,594   11   28   89   304  20,026 (2.2%) 
Chronic Kidney 
Disease 
156,970   127   628   1,361   4,886  163,972 (4.3%) 
Other Immune System 
Diseases 
85,432   153   588   1,107   2,829  90,109 (5.2%) 
Generalized 
Malignancy 
343,872   188   719   1,629   6,722  353,130 (2.6%) 
HIV  18,644   152   1,663   1,527   1,741  23,727 (21.4%) 
Hodgkin's Disease  6,732   15   76   93   255  7,171 (6.1%) 
Radiation Therapy  72,598   78   362   665   2,149  75,852 (4.3%) 
Leukemia  13,761   46   134   281   710  14,932 (7.8%) 
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Lymphoma  24,444   42   189   325   938  25,938 (5.8%) 
Multiple Myeloma  5,926   37   117   184   410  6,674 (11.2%) 
Nephrotic Syndrome  4,354   5   23   54   153  4,589 (5.1%) 
Solid Organ Transplant  7,114   43   150   250   575  8,132 (12.5%) 
 
Table 3.4 provides results from the output of the multiple logistic regression 
model with having a PCV13 claim as the predicted outcome. All covariates except age 
30-39 vs 19-29, urban residence, CSF leak, were significant at the 5% level. Subjects 
who were male, had residence outside of the Northeast and unknown regions, or had an 
inpatient stay had greater odds of having a PCV13 claim. Subjects of increasing age and 
increasing number of outpatient visits were more likely to have a claim. Odds were 
reduced when subjects had sickle cell disease or other hemoglobinopathy, or generalized 
malignancy. Odds were increased in subjects with a cochlear implant, asplenia, chronic 
kidney disease (CKD), other immune system diseases, HIV, Hodgkin's disease, radiation 
therapy, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, or solid organ 
transplant. 
Table 3.4 Adults 19-64 Years of Age with High Risk Indication, Odds of Having a PCV13 
Claim 
Effect Odds Ratio Estimate 95% CI 
Demographics 
Age 30-39 vs 19-29 1.108 0.997 1.231 
Age 40-49 vs 19-29 *1.413 1.284 1.556 
Age 50-59 vs 19-29 *2.049 1.867 2.249 
Age 60-64 vs 19-29 *3.486 3.173 3.831 
Male vs Female *1.215 1.182 1.249 
North Central vs Northeast *1.386 1.33 1.444 
South vs Northeast  *1.058 1.02 1.097 
West vs Northeast  *1.424 1.363 1.488 
Region unknown vs Northeast *0.598 0.41 0.872 
Urban vs Rural 1.011 0.968 1.056 
Healthcare Utilization 
Outpatient days 2nd vs 1st quartile† *1.386 1.326 1.449 
Outpatient days 3rd vs 1st quartile† *1.860 1.780 1.942 
Outpatient days 4th vs 1st quartile† *2.601 2.488 2.719 
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Inpatient Claim *1.096 1.064 1.130 
Diagnosis or Condition 
Chronic Kidney Disease *1.115 1.072 1.159 
Other Immune System Diseases *1.427 1.373 1.484 
Generalized Malignancy *0.724 0.698 0.752 
HIV *12.893 12.327 13.485 
Hodgkin's Disease *1.646 1.476 1.834 
Radiation Therapy *1.048 1.003 1.096 
Leukemia *1.742 1.627 1.865 
Lymphoma *1.208 1.135 1.286 
Multiple Myeloma *2.271 2.089 2.467 
Nephrotic Syndrome *1.247 1.087 1.432 
Solid Organ Transplant *2.425 2.252 2.610 
C-statistic = 0.764 
†Quartile breakpoints are <31, 31-54, 55-92, and >92 days, for quartiles 1-4 respectively 
*Denotes significant value 
For diagnosis or condition based covariates, the reference group is not having the 
diagnosis or condition 
 
Table 3.5 provides summary descriptive statistics for the subjects in Cohort 2, 
excluding individuals with inpatient claims between 2012 and 2015. The overall PCV13 
claim rate was 3.3%, slightly lower than the overall vaccination rate when including 
subjects with inpatient claims. PCV13 claim rates are similar compared to analysis not 
excluding subjects with inpatient claims with the following exceptions, subjects over 50 
years of age, or those with multiple myeloma, or solid organ transplants; these groups 
were less likely to receive vaccination. Outpatient stays are a mean 20% less compared to 
the analysis including subjects with inpatient claims. 
Table 3.5 Adults 19-64 Years of Age with High Risk Indication, Excluding Individuals 
with Inpatient Claims, Descriptive Table 
Year of PCV13 Claim None 2012 2013 2014 2015 All groups**  
(% vaccinated) 
Demographics 
n 431,042   388  2,241  3,267   9,353  446,291 (3.4%) 
Age Mean  52   50   49   52   56  52 
Age Standard 
Deviation 
9.34 9.26 9.27 9.68 8.02 9.33 
Age 19-29  12,829   18   79   114   122  13,162 (2.5%) 
Age 30-39  33,043   30   262   262   349  33,946 (2.7%) 
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Age 40-49  87,905   79   677   659   1,089  90,409 (2.8%) 
Age 50-59 186,095   208   940  1,319   3,517  192,079 (3.1%) 
Age 60-64 111,170   53   283   913   4,276  116,695 (4.7%) 
Male 179,071   218  1,543  1,916   4,538  187,286 (4.4%) 
Female 251,971   170   698  1,351   4,815  259,005 (2.7%) 
Northeast  98,519   78   411   673   1,895  101,576 (3.0%) 
North Central  81,015   67   369   666   2,038  84,155 (3.7%) 
South 187,191   176  1,093  1,360   3,707  193,527 (3.3%) 
West  63,306   67   363   561   1,703  66,000 (4.1%) 
Region Unknown  1,011   -     5   7   10  1,033 (2.1%) 
Urban 382,607   348  2,093  2,980   8,346  396,374 (3.5%) 
Rural  47,793   40   148   287   997  49,265 (3.0%) 
Healthcare Utilization 
Outpatient Days Mean  57   73   59   67   73  57 
Outpatient Days 
Standard Deviation 
49.24 50.83 52.28 52.96 55.58 49.49 
# of Patients with 
Inpatient Claim 
 -   -   -   -   -  0 (0%) 
Diagnosis 
Cochlear Implant  1,021   1   49   46   76  1,193 (14.4%) 
Cerebrospinal Fluid 
Leak 
 1,450   2   1   9   21  1,483 (2.2%) 
Asplenia  861   4   36   55   103  1,059 (18.7%) 
Sickle Cell Disease or 
Other 
Hemoglobinopathy 
 14,648   6   17   46   189  14,906 (1.7%) 
Chronic Kidney 
Disease 
101,954   79   337   697   2,548  105,615 (3.5%) 
Other Immune System 
Diseases 
 57,112   89   286   536   1,460  59,483 (4.0%) 
Generalized 
Malignancy 
237,279   115   388   839   3,816  242,437 (2.1%) 
HIV  14,555   127  1,378  1,249   1,394  18,703 (22.2%) 
Hodgkin's Disease  4,727   8   35   40   141  4,951 (4.5%) 
Radiation Therapy  37,922   42   127   213   890  39,194 (3.2%) 
Leukemia  9,132   28   54   120   362  9,696 (5.8%) 
Lymphoma  16,411   24   87   147   502  17,171 (4.4%) 
Multiple Myeloma  3,349   16   28   40   131  3,564 (6.0%) 
Nephrotic Syndrome  2,502   4   8   20   68  2,602 (3.8%) 
Solid Organ 
Transplant 
 2,611   19   32   48   122  2,832 (7.8%) 
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Table 3.6 provides results from the output of the multiple logistic regression 
model with having a PCV13 claim as the predicted outcome, excluding individuals with 
inpatient claims between 2012 and 2015. All covariates except Region Unknown vs. 
Northeast, urban residence, CSF leak, and radiation therapy, were significant at the 5% 
level. Odds ratios were similar to the analysis excluding outpatient stays.  
Table 3.6 Adults 19-64 Years of Age with High Risk Indication, Excluding Individuals 
with Inpatient Claims, Odds of Having a PCV13 Claim 
Effect Odds Ratio Estimate 95% CI 
Demographics 
Age 30-39 vs 19-29 *1.226 1.074 1.399 
Age 40-49 vs 19-29 *1.523 1.350 1.718 
Age 50-59 vs 19-29 *2.193 1.950 2.466 
Age 60-64 vs 19-29 *4.065 3.609 4.580 
Male vs Female *1.269 1.224 1.315 
North Central vs Northeast *1.473 1.397 1.553 
South vs Northeast  *1.140 1.089 1.194 
West vs Northeast  *1.474 1.395 1.558 
Region Unknown vs Northeast 0.717 0.461 1.116 
Urban vs Rural 1.009 0.954 1.068 
Healthcare Utilization 
Outpatient days 2nd vs 1st quartile† *1.425 1.358 1.496 
Outpatient days 3rd vs 1st quartile† *1.922 1.830 2.019 
Outpatient days 4th vs 1st quartile† *2.548 2.418 2.684 
Diagnosis 
Asplenia *10.158 8.611 11.982 
Sickle Cell Disease or Other 
Hemoglobinopathy 
*0.781 0.685 0.890 
Chronic Kidney Disease *1.109 1.051 1.171 
Other Immune System Diseases *1.369 1.296 1.447 
Generalized Malignancy *0.689 0.654 0.726 
HIV *15.287 14.434 16.19 
Hodgkin's Disease *1.568 1.353 1.816 
Radiation Therapy 1.064 0.997 1.134 
Leukemia *1.792 1.631 1.968 
Lymphoma *1.211 1.113 1.318 
Multiple Myeloma *1.584 1.370 1.830 
Nephrotic Syndrome *1.316 1.071 1.616 
Solid Organ Transplant *2.209 1.914 2.550 
C-statistic=0.777 
†Quartile breakpoints are <31, 31-54, 55-92, and >92 days, for quartiles 1-4 respectively 
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*Denotes significant value 
For diagnosis or condition based covariates, the reference group is not having the 
diagnosis or condition 
Cohort 3: Adults ≥ 65 years of age 
A total of 1,262,531 subjects were identified, 18% of which had a PCV13 claim.  
Table 3.7 provides summary descriptive statistics for the subjects in Cohort 3. The 
table is subdivided by year of PCV13 claim. Subjects with a PCV13 claim have a mean 
14% greater number of outpatient claim days compared to subjects without a PCV13 
claim. Rate of having a PCV13 was highest at ages 70-79.  
Table 3.7 Adults ≥65 Years of Age, Descriptive Table 
Year of PCV13 
Claim 
None 2012 2013 2014 2015 All groups** 
(% vaccinated) 
Demographics 
n 1,069,894  1,212  3,644  20,148  167,633  1,262,531 (18.0%) 
Age Mean  76   72   74   76   77   76  
Age Standard 
Deviation 
7.71 7.39 7.33 6.96 6.80 7.59 
Age 65-69  168,627   422   909   3,291   21,634  194,883 (15.6%) 
Age 70-79  507,455   506  1,680  10,202   88,983  608,826 (20.0%) 
Age 80-89  300,323   223   832   5,623   48,217  355,218 (18.3%) 
Age 90-99  63,733   25   101   846   8,024  72,729 (14.1%) 
Age 100+  906   -     2   6   48  962 (6.2%) 
Male  478,276   541  1,669   9,094   74,100  563,680 (17.9%) 
Female  591,618   671  1,975  11,054   93,533  698,851 (18.1%) 
Northeast  249,358   372   993   5,241   34,342  290,306 (16.4%) 
North Central  368,569   329  1,239   6,740   68,147  445,024 (20.7%) 
South  341,588   432  1,164   4,407   44,320  391,911 (14.7%) 
West  108,043   79   248   3,748   20,762  132,880 (23.0%) 
Region Unknown  2,336   -     -     12   62  2,410 (3.2%) 
Urban  899,255  1,059  3,145  17,796  144,126  1,065,381 (18.5%) 
Rural  168,867   153   499   2,340   23,455  195,314 (15.7%) 
Healthcare Utilization 
Mean Outpatient 
Days 
 70   93   94   88   80   72  
Outpatient Days 
Standard 
Deviation 
66.17 68.01 77.80 67.33 62.69 65.91 
# of Patients with 
Inpatient Claim 
 232,294   281   890   4,504   33,476  271,445 (16.9%) 
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# Patients with 
High Infection 
Risk 
 365,616   506  1,557   842   61,874  430,395 (17.7%) 
 
 Table 3.8 provides results from the output of the multiple logistic regression 
model with having a PCV13 claim as the predicted outcome. All covariates except gender 
were significant at the 5% level. Subjects 70-79 or 80-89 years of age, who had residence 
in the North Central or West regions, no high infection risk conditions, or no inpatient 
stays, had greater odds of having a PCV13 claim. Subjects with increasing number of 
outpatient visits were more likely to have a claim. 
Table 3.8 Adults ≥65 Years of Age, Odds of Having a PCV13 Claim 
Effect Odds Ratio 
Estimate 
95% CI 
Demographics 
Age 70-79 vs Age 65-69 *1.229 1.211 1.248 
Age 80-89 vs Age 65-69 *1.086 1.068 1.103 
Age 90-99 vs Age 65-69 *0.841 0.820 0.863 
Age 100+ vs Age 65-69 *0.394 0.301 0.517 
Male vs Female 1.003 0.993 1.013 
North Central vs Northeast *1.339 1.321 1.356 
South vs Northeast  *0.927 0.914 0.940 
West vs Northeast  *1.447 1.422 1.473 
Region Unknown vs Northeast *0.270 0.214 0.341 
Urban vs Rural *1.177 1.160 1.194 
High Infection Risk Condition *0.987 0.976 0.997 
Healthcare Utilization 
Outpatient days 2nd vs 1st quartile† *1.841 1.813 1.868 
Outpatient days 3rd vs 1st quartile† *2.104 2.071 2.137 
Outpatient days 4th vs 1st quartile† *2.355 2.317 2.393 
Inpatient Claim vs no inpatient claim *0.761 0.751 0.770 
C-statistic=0.603 
†Quartile breakpoints are <30, 30-60, 61-97, and >97 days, for quartiles 1-4 respectively 
*Denotes significant value 
 
Table 3.9 provides summary descriptive statistics for the subjects in Cohort 3, 
excluding individuals with inpatient claims or high infection risk conditions between 
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2012 and 2015. The overall PCV13 claim rate was 14.3%, compared to 18% when 
including subjects with inpatient claims or high infection risk conditions. PCV13 claim 
rates were correspondingly lower in all groups, with no groups exhibiting a higher rate.  
Table 3.9 Adults ≥65 Years of Age, Excluding Individuals with Inpatient Claims and 
Individuals with High Risk Conditions, Descriptive Table 
Year of PCV13 Claim None 2014 2015 All groups**  
(% vaccinated) 
Demographics 
n  589,227   9,072  89,056  687 (14.3%) 
Age Mean  75   75   75  75 
Age Standard Deviation 7.48 6.59 6.49 7.35 
Age 65-69  111,617   1,735   
13,839  
127 (12.2%) 
Age 70-79  293,722   4,890  50,224  349 (15.8%) 
Age 80-89  138,943   2,124  21,522  163 (14.5%) 
Age 90-99  26,826   275   3,098  30 (11.2%) 
Age 100+  494   1   16  0.5 (3.3%) 
Male  246,809   3,763  36,472  287 (14.0%) 
Female  342,418   5,309  52,584  400 (14.5%) 
Northeast  138,761   2,324  18,253  159 (12.9%) 
North Central  199,239   2,984  36,050  238 (16.4%) 
South  189,105   1,957  23,488  215 (11.9%) 
West  60,446   1,802  11,232  73 (17.7%) 
Region Unknown  1,676   5   33  1.7 (2.2%) 
Urban  490,754   8,029  76,091  575 (14.6%) 
Rural  97,182   1,038  12,935  111 (12.6%) 
Healthcare Utilization 
Mean Outpatient Days  50   67   62  52 
Outpatient Days Standard Deviation 45.66 48.87 46.34 46.05 
# Patients with Inpatient Stays 0 0 0 0 (0.0%) 
# Patients with High Risk 0 0 0 0 (0.0%) 
 
Table 3.10 provides results from the output of the multiple logistic regression 
model with having a PCV13 claim as the predicted outcome, excluding individuals with 
inpatient claims or high infection risk conditions between 2012 and 2015. All covariates 
except gender were significant at the 5% level. Odds ratios were similar to the analysis 
excluding outpatient stays.  
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Table 3.10 Adults ≥65 Years of Age, and Individuals with High Risk Conditions, Odds of 
Having a PCV13 Claim  
Effect Odds Ratio Estimate 95% CI 
Age 70-79 vs Age 65-69 *1.268 1.249 1.288 
Age 80-89 vs Age 65-69 *1.104 1.086 1.122 
Age 90-99 vs Age 65-69 *0.844 0.822 0.867 
Age 100+ vs Age 65-69 *0.384 0.291 0.507 
Male vs Female 0.994 0.984 1.004 
North Central vs Northeast *1.342 1.324 1.360 
South vs Northeast  *0.923 0.910 0.936 
West vs Northeast  *1.480 1.454 1.507 
Region Unknown vs Northeast *0.269 0.212 0.341 
Urban vs Rural *1.178 1.161 1.195 
Outpatient days 2nd vs 1st 
quartile† 
*1.788 1.761 1.815 
Outpatient days 3rd vs 1st 
quartile† 
*1.977 1.947 2.008 
Outpatient days 4th vs 1st 
quartile† 
*2.097 2.065 2.129 
C-statistic=0.598 
†Quartile breakpoints are <30, 30-60, 61-97, and >97 days, for quartiles 1-4 respectively 
*Denotes significant value  
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Section Four: Discussion 
Across all cohorts, the most consistent supportive covariate for vaccination was 
having a greater number of outpatient visits. Residence in North Central and West 
regions were generally supportive of vaccination. Urban residence was supportive in all 
cohorts, but not significantly so in Cohort 2. Gender inconsistently predicted vaccination, 
at times being protective against vaccination, supportive for vaccination, and non-
significantly affecting vaccination. Similarly, having an inpatient stay was supportive for 
vaccination and protective against and vaccination in Cohorts 2 and 3 respectively. 
Further discussion of each cohort follows.  
Cohort 1: Children < 36 months of age 
 The overall measured rate of completed PCV13 vaccination in children under 36 
months of age was 78%, comparable to the approximately 83% pneumococcal 
vaccination rate reported for children under 36 months of age between 2010-2015.7 This 
provides evidence to suggest good capture of vaccinations.  
Cohort 2: Adults 19-64 years of age with high risk indication 
The overall measured rate of PCV13 vaccination in adults 19-64 years of age with 
high infection risk conditions was 3.8%. This is a lower coverage rate than the 23% 
estimated by the NHIS.6 This is expected as the NHIS estimate includes vaccination with 
both PCV13 and the much older PPSV23; additionally, the NHIS estimate includes adults 
with moderate-high infection risk conditions, and it is unclear how this effects the 
reported percent covered. Subjects were progressively more likely to have a claim for 
PCV13 in older age groups. Subjects who had more outpatient visits were progressively 
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more likely to have a claim for PCV13; however, this trend was not observed for HIV 
and sickle cell or other hemoglobinopathies; instead, individuals with these diagnoses 
were equally likely to have a PCV13 claim regardless of how frequently they had 
outpatient visits. This suggests that subjects and their physicians have a greater awareness 
of the need for proactively preventing infectious diseases. 
Cohort 3: Adults ≥ 65 years of age 
The overall measured rate of PCV13 vaccination in adults over 65 years of age 
was 18%. As with Cohort 2, this is lower than NHIS reported rate of 64%.5 This is an 
expected result as the NHIS estimate includes both PPSV23 and PCV13 vaccination. 
Females, persons over 75 years of age, and persons residing in a rural area, or the 
Midwest or West region have higher reported rates of pneumococcal vaccination.6 As 
with Cohort 2, individuals were progressively more likely to be vaccinated than younger 
individuals; however, this trend reversed in the age groups containing subjects aged 80 
and older. With the exception of urban residence, these same factors were found to have 
higher rates of PCV13 vaccination in table 3.7; although gender was found to be non-
significant when correcting for all other covariates in table 3.8.  
Limitations 
Insurance claims data are collected for billing purposes rather than tracking 
patient health status. This leads to multiple consequences which hamper the utility of 
datasets based on claims data, such as the Truven Health MarketScan® databases used in 
this analysis. One such consequence is that patient details such as income, race, and 
physician and lab reported values are not available. Another consequence is that 
diagnosis and service codes may not be specific to a condition of interest. In the case of 
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pneumococcal vaccination, multiple diagnosis and service codes may validly be used to 
file a claim for PCV13 vaccination, some of which may also be used for PPSV 
vaccination. This study followed a conservative approach, including only service codes 
specific to PCV13. Even so, providers may mistakenly use the wrong billing code when 
submitting a claim; such unintentional misreporting is not possible to distinguish from 
genuinely provided services. 
In the outpatient setting, a maximum of four diagnoses may be reported for an 
outpatient claim, leading physicians to only report diagnoses pertinent to services 
provided, thus limiting the ability to determine high infection risk conditions in Cohort 2.  
In the inpatient setting, claims are typically made via a prospective payment 
system, wherein claims are made for an overall service provided, not specific procedures 
such as PCV13 administration. This is of particular concern, because from 2012 to 2014, 
the Joint Commission included pneumococcal vaccination as a performance 
measurement, encouraging hospitals provide PCV13 to qualifying patients.26 In 
recognition of this practice, separate analyses were performed for Cohorts 2 and 3, which 
excluded subjects with inpatient claims. In addition, for Cohort 3, this secondary analysis 
also excluded subjects with high infection risk conditions, as this group qualified for 
vaccination at earlier dates than subjects without high infection risk conditions.  
To assess the accuracy of measured prevalence of high infection risk diseases in 
Cohort 2, national rates of high infection risk diseases were reviewed, and are reported in 
Appendix F. Measured rates were overall similar to national rates, with some exceptions. 
Conditions in which measured rates were low compared to national averages include 
asplenia and solid organ transplant, both of which may be attributable to infrequent 
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claims being made which include pertinent diagnoses codes. Chronic kidney disease was 
also measured at rates lower than national averages, and this may be attributable to such 
persons becoming eligible for Medicare prior to 65 years of age. Sickle cell disease was 
measured at rates above national averages, this may be due to misreporting of sickle cell 
trait as sickle cell disease. Prevalence of CSF leak, radiation therapy, nephrotic 
syndrome, and other immune system diseases in the U.S. are not well defined, and 
therefore were not assessed in comparison to measured rates.  
Last, because the Truven MarketScan® databases contain subjects whose 
insurance coverage is provided by their employer, this analysis may not be generalizable 
to all persons residing in the U.S, particularly those with lower incomes who may rely on 
Medicaid for health insurance. Subjects may also have used an alternate insurance for 
vaccination, or may have paid for vaccination in cash, either of which would lead to 
undocumented vaccination. 
The sum of the limitations and methods used in this study indicate that measured 
vaccination prevalence rates are more likely to underestimate than overestimate.  
Conclusions 
At the time of writing, there is no assessment of PCV13 coverage in high 
infection risk adults in the U.S. Insurance claims records are primarily kept for billing 
purposes, rather than as a means to record patient health status. Subsequently, it is 
difficult to determine the health status of individuals contained in datasets derived from 
these records. Methods for assessing the prevalence of PCV13 vaccination that have not 
been reported in literature include analysis of hospital electronic health records to 
determine true inpatient rates of PCV13 administration. The Medical Expenditure Panel 
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Survey (MEPS), which unifies detailed surveys provided to individuals with their health 
records may offer deeper insight into vaccination rates. Published survey questions 
include “Have you ever had a pneumonia shot? A pneumonia shot or pneumococcal 
vaccine is usually only given once or twice in a person's lifetime,” which precludes the 
possibility of differentiating between PPSV23 and PCV13.33 Overall there is an unmet 
need to track vaccination status. A potential solution to the difficulty in assessing 
vaccination prevalence would be the creation of a national vaccine registry, to which all 
providers must report administered vaccines; however, for such a registry to be 
maximally useful for research purposes, it would require patient diagnostic information, 
or ability to link to other datasets. 
National estimates of pneumococcal vaccination indicate rates below Healthy 
People 2020 goals. This study builds upon these studies by revealing the specific 
characteristics of patients who are less likely to be vaccinated. By identifying these 
individuals, providers and insurers may more effectively try to reach these patients and 
make a recommendation for pneumococcal vaccination.  
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Appendix A: Medical conditions at moderate and high risk for infection 
Medical indication 
Moderate risk medical 
condition 
High risk medical condition 
Immunocompetent 
persons 
Alcoholism Cochlear implant 
Chronic heart disease a Cerebrospinal fluid leak 
Chronic liver disease   
Chronic lung disease b  
Cigarette smoking  
Diabetes mellitus  
Persons with 
functional or anatomic 
asplenia 
 Congenital or acquired asplenia 
 Sickle cell disease / other 
hemoglobinopathies 
Immunocompromised 
persons 
 Chronic renal failure 
 Congenital or acquired 
immunodeficiencies c  
 Generalized malignancy 
 HIV infection 
 Hodgkin disease 
 Iatrogenic immunosuppression d 
 Leukemia 
 Lymphoma 
 Multiple myeloma 
 Nephrotic syndrome 
 Solid organ transplant 
 
a. Including congestive heart failure and cardiomyopathies, and in children cyanotic 
congenital heart disease and cardiac failure. 
b. Including chronic obstructive pulmonary disease, emphysema, and asthma 
c. Includes B- (humoral) or T-lymphocyte deficiency, complement deficiencies 
(particularly C1, C2, C3, and C4 deficiencies), and phagocytic disorders (excluding 
chronic granulomatous disease). 
d. Diseases requiring treatment with immunosuppressive drugs, including long-term 
systemic corticosteroids and radiation therapy. 
Adapted from 34  
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Appendix B: Streptococcus pneumoniae vaccine serotype coverage 
Streptococcus pneumoniae serotype Vaccine 
PPSV23 PCV7 PCV13 
1 ✓  ✓ 
2  ✓   
3 ✓  ✓ 
4  ✓ ✓ ✓ 
5 ✓  ✓ 
6A    ✓ 
6B ✓ ✓ ✓ 
7F  ✓  ✓ 
8 ✓   
9N  ✓   
9V ✓ ✓ ✓ 
10A ✓   
11A ✓   
12F ✓   
14 ✓ ✓ ✓ 
15B ✓   
17F ✓   
18C ✓ ✓ ✓ 
19A ✓  ✓ 
19F ✓ ✓ ✓ 
20 ✓   
22F ✓   
23F ✓ ✓ ✓ 
33F ✓   
 
As of 2011, 92 Pneumococcal serotypes have been documented.1 
Additional Sources: Vaccine package inserts for PCV7, PCV13, and PPSV23. 35-37 
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Appendix C: PCV13 catch-up guidance for children 4 months - 18 years of age 
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0 ⟶  ⟶  
Give Dose 1 
Today  
Give Dose 2 at 
least 4 weeks after 
Dose 1  
1 
Dose 1 was 
given 
before 7 
months of 
age  
It has been at 
least 4 weeks 
since Dose 1  
Give Dose 2 
today  
Give Dose 3 at 
least 8 weeks after 
Dose 2 and at 12 
months of age or 
older (Final Dose) 
It has not been 4 
weeks since 
Dose 1  
No Dose today  
Give Dose 2 at 
least 4 weeks after 
Dose 1  
Dose 1 was 
given at 7 
months or 
older  
It has been at 
least 4 weeks 
since Dose 1  
Give Dose 2 
today  
Give Dose 3 at 
least 8 weeks after 
Dose 2 and at 12 
months of age or 
older (Final Dose)  
It has not been 4 
weeks since 
Dose 1  
No Dose today  
Give Dose 2 at 
least 4 weeks after 
Dose 1  
2 
Dose 2 was 
given 
It has been at 
least 4 weeks 
Give Dose 3 
today  
Give Dose 4 at 
least 8 weeks after 
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before 7 
months of 
age  
since Dose 2  Dose 3 and at 12 
months of age or 
older (Final Dose)  
It has not been 4 
weeks since 
Dose 2  
No Dose today  
Give Dose 3 at 
least 4 weeks after 
Dose 2  
Dose 2 was 
given at 7 
months or 
older  
⟶  No Dose today  
Give Dose 3 at 
least 8 weeks after 
Dose 2 and at 12 
months of age or 
older (Final Dose)  
1
2
-2
3
 M
o
n
th
s 
 
0 ⟶  ⟶  
Give Dose 1 
today 
Give Dose 2 at 
least 8 weeks after 
Dose 1 (Final 
Dose) 
1 
Dose 1 was 
given 
before 12 
months of 
age 
It has been at 
least 4 weeks 
since Dose 1 
Give Dose 2 
today 
Give Dose 3 at 
least 8 weeks after 
Dose 2 (Final 
Dose)  
It has not been 
at least 4 weeks 
since Dose 1 
No Dose today  
Give Dose 2 at 
least 4 weeks after 
Dose 1  
Dose 1 was 
given at 12 
months of 
age or older  
It has been at 
least 8 weeks 
since Dose 1 
Give Dose 2 
today (Final 
Dose) 
No additional 
doses needed  
It has not been 
at least 48 
weeks since 
Dose 1 
No Dose today  
Give Dose 2 at 
least 8 weeks after 
dose 1 (Final 
Dose)  
2 
Both doses 
were given 
before 12 
months of 
age 
It has been at 
least 8 weeks 
since Dose 2 
Give Dose 3 
today (Final 
Dose) 
No additional 
doses needed  
It has not been 8 
weeks since 
Dose 2 
No Dose today  
Give Dose 3 at 
least 8 weeks after 
Dose 2 (Final 
Dose)  
At least one 
dose was 
given at 12 
months of 
age or older 
It has been at 
least 8 weeks 
since Dose 2 
Give Dose 3 
today (Final 
Dose) 
No additional 
doses needed  
It has not been 8 
weeks since 
Dose 2 
No Dose today  
Give Dose 3 at 
least 8 weeks after 
Dose 2 (Final 
Dose)  
3 
All doses 
were given 
before 12 
It has been at 
least 8 weeks 
since Dose 3 
Give Dose 4 
today (Final 
Dose) 
No additional 
doses needed  
 
 29 
months of 
age  
It has not been 
at least 8 weeks 
since Dose 3 
No Dose today  
Give Dose 4 at 
least 8 weeks after 
Dose 3 (Final 
Dose)  
1 or more 
doses was 
given at 12 
months of 
age or older  
⟶  No Dose today  
No additional 
doses needed  
2
4
-5
9
 M
o
n
th
s 
 
0 ⟶  ⟶  
Give Dose 1 
today 
No additional 
doses needed  
1 
Dose 1 was 
given 
before 24 
months of 
age 
It has been at 
least 8 weeks 
since the first 
dose 
Give Dose 2 
today (Final 
Dose) 
no additional 
doses needed  
It has not been 
at least 8 weeks 
since the first 
dose 
No Dose today  
Give Dose 2 (Final 
Dose) at least 8 
weeks after Dose 1 
Dose was 
given at 24 
months or 
older 
⟶  No Dose today  
No additional 
doses needed  
2 
Dose 2 was 
given 
before 24 
months of 
age 
It has been at 
least 8 weeks 
since Dose 2 
Give Dose 3 
today (Final 
Dose) 
No additional 
doses needed  
It has not been 8 
weeks since 
Dose 2 
No Dose today  
Give dose 3 (Final 
Dose) at least 8 
weeks after Dose 2 
Dose 2 was 
given at 24 
months of 
age or older 
⟶  No Dose today  
No additional 
doses needed  
3 
All 3 doses 
were given 
before 12 
months of 
age 
⟶  
Give Dose 4 
today (Final 
Dose) 
No additional 
doses needed  
 
As listed in 38 
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Appendix D: ICD-9 diagnosis codes 
Condition ICD-9 diagnosis code  
Cochlear implant procedure code: V5273, 69930, 92601-92604,  
 L8614-L8619, L8621-L8624, L8627-L8629,  
Cerebrospinal fluid leak 34981, 38861, V452  
Congenital or acquired asplenia 7590 or procedure code: 38100, 38102, 28120 
Sickle cell disease or other hemoglobinopathy 282.4x, 282.6x, 282.7 
Chronic kidney disease V420, V451, V56.x, 403.x, 404.x, 
 582.x, 583.x, 585.x, 7530, 7925 
Congenital or acquired immunodeficiency 2790.x, 2791.1, 2791.2, 2791.3, 2792, 
 2793, 2794.x, 2798, 2799  
Generalized malignancy 185, 140.x-165.x, 170.x-172.x, 174.x-176.x, 
 179.x-184.x, 186.x, 199.x, 202.x, 203.8x  
 208.x 
HIV infection V08, 042.x, 043.x, 044.x, 27910, 27919, 
 7953, 7958, 79571 
Hodgkin’s disease 201.x 
Radiation therapy V580, V581.x, V661, V662, V671, V672 
Leukemia 202.4, 203.1x, 204.x-208.x 
Lymphoma 200.x, 202.0x-202.2x, 202.7x, 202.8x, 202.9x 
Multiple myeloma 203.0x  
Nephrotic syndrome 581.x 
Solid Organ Transplant 2795.x, 9968.x 
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Appendix E: Correlation Matrices 
Cohort 1 Pearson Correlation Coefficient Correlation Matrix 
 Gender Urban Residence Region Outpatient Quartile 
Gender 1 -0.0018 0.00019 0.08182* 
Region 0.00019 -0.14368* 1 -0.13717* 
Urban Residence -0.0018 1 -0.14368* 0.01797* 
Outpatient Quartile 0.08182* 0.01797* -0.13717* 1 
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Appendix F: Rates of High Infection Risk Disease in the U.S.  
 Reported in Literature Measured 
 n % total n % total 
Total Population, 19-64 Years of 
Age 
 194,296,08739  100.00%  8,214,322  100.00% 
Cochlear Implant  41,00040  0.02%  1,457  0.02% 
Asplenia  272,01541  0.14%  1,643  0.02% 
Sickle Cell Disease   62,93142  0.03%  20,026  0.24% 
Chronic Kidney Disease 15,306,38143,44  7.88%  163,972  2.00% 
Generalized Malignancy  6,343,72045  3.26%  353,130  4.30% 
HIV  895,94046,47  0.46%  23,727  0.29% 
Hodgkin's Disease  142,64148  0.07%  7,171  0.09% 
Leukemia  387,72849  0.20%  14,932  0.18% 
Lymphoma  282,67250  0.15%  25,938  0.32% 
Multiple Myeloma  44,45251  0.02%  6,674  0.08% 
Solid Organ Transplant  534,24952  0.27%  8,132  0.10% 
Cerebrospinal fluid leak, radiation therapy, nephrotic syndrome, and other Immune 
system diseases U.S. prevalence not well defined 
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